😴Sleep & Recovery

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and obesity management, with cardiovascular and neuroprotective benefits.

An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, producing unprecedented weight loss of up to 24% in clinical trials.

An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with proven cardiovascular benefits and convenient single-use pen delivery.

The first GLP-1 receptor agonist approved for type 2 diabetes, originally derived from Gila monster venom, available in twice-daily and once-weekly formulations.

A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.

An orally active, non-peptide growth hormone secretagogue that mimics ghrelin to raise GH and IGF-1 levels for up to 24 hours per dose, with notable effects on sleep, appetite, and body composition.

An investigational dual glucagon and GLP-1 receptor agonist being developed for obesity and MASH (metabolic dysfunction-associated steatohepatitis) with significant liver fat reduction.

A modified growth hormone-releasing hormone fragment with a short half-life (~30 minutes) that stimulates pulsatile growth hormone release, closely mimicking the body's natural GH secretion pattern.

The first 29 amino acids of natural GHRH, previously FDA-approved for pediatric GH deficiency. Now widely used off-label for anti-aging GH optimization as a safer alternative to direct HGH therapy.

A mitochondria-derived peptide that acts as an exercise mimetic, improving metabolic health, insulin sensitivity, and physical performance through AMPK activation.

A long-acting growth hormone-releasing hormone (GHRH) analog with a Drug Affinity Complex that extends its half-life to 6-8 days, producing sustained elevated growth hormone and IGF-1 levels.